Abstract:Importance: It is critically important to improve our ability to diagnose and track Alzheimer disease (AD) as early as possible. Individuals with autosomal dominant forms of AD can provide clues as to which and when biological changes are reliably present prior to the onset of clinical symptoms.Objective: To characterize the associations between amyloid and tau deposits in the brains of cognitively unimpaired and impaired carriers of presenilin 1 (PSEN1) E280A mutation.Design, Setting, and Participants: In this cross-sectional imaging study, we leveraged data from a homogeneous autosomal dominant AD kindred, which allowed us to examine measurable tau deposition as a function of individuals' proximity to the expected onset of dementia. Cross-sectional measures of carbon 11-labeled Pittsburgh Compound B positron emission tomography (PET) and flortaucipir F 18 (previously known as AV 1451, T807) PET imaging were assessed in 24 PSEN1 E280A kindred members (age range, 28-55 years), including 12 carriers, 9 of whom were cognitively unimpaired and 3 of whom had mild cognitive impairment, and 12 cognitively unimpaired noncarriers.Main Outcomes and Measures: We compared carbon 11-labeled Pittsburgh Compound B PET cerebral with cerebellar distribution volume ratios as well as flortaucipir F 18 PET cerebral with cerebellar standardized uptake value ratios in mutation carriers and noncarriers. Spearman correlations characterized the associations between age and mean cortical Pittsburgh Compound B distribution volume ratio levels or regional flortaucipir standardized uptake value ratio levels in both groups.Results: Of the 24 individuals, the mean (SD) age was 38.0 (7.4) years, or approximately 6 years younger than the expected onset of clinical symptoms in carriers. Compared with noncarriers, cognitively unimpaired mutation carriers had elevated mean cortical Pittsburgh Compound B distribution volume ratio levels in their late 20s, and 7 of 9 carriers older than 30 years reached the threshold for amyloidosis (distribution volume ratio level > 1.2). Elevated levels of tau deposition were seen within medial temporal lobe regions in amyloid-positive mutation carriers 6 years before clinical onset of AD in this kindred. Substantial tau deposition in the neocortex was only observed in 1 unimpaired carrier and in those with mild cognitive impairment. β-Amyloid uptake levels were diffusely elevated in unimpaired carriers approximately 15 years prior to expected onset of mild cognitive impairment. In carriers, higher levels of tau deposition were associated with worse performance on the Mini-Mental State Examination (entorhinal cortex: r = -0.60; P = .04; inferior temporal lobe: r = -0.54; P = .06) and the Consortium to Establish a Registry for Alzheimer Disease Word List Delayed Recall (entorhinal cortex: r = -0.86; P < .001; inferior temporal lobe: r = -0.70; P = .01).Conclusions and Relevance: The present findings add to the growing evidence that molecular markers can characterize biological changes associated with AD in individuals who are still cognitively unimpaired. The findings also suggest that tau PET imaging may be useful as a biomarker to distinguish individuals at high risk to develop the clinical symptoms of AD and to track disease progression.

Associations of tau, Aβ, and brain volume of the Papez circuit with cognition in Alzheimer's disease

Clinical and Neuroimaging Differences Between Posterior Cortical Atrophy and Typical Amnestic Alzheimer’s Disease Patients at an Early Disease Stage

Correlation of hippocampal volume and cognitive performances in patients with either mild cognitive impairment or Alzheimer's disease.

Tau pathology and relative cerebral blood flow are independently associated with cognition in Alzheimer's disease

Tau as a biomarker of cognitive impairment and neuropsychiatric symptom in Alzheimer's disease

Relationships between plasma biomarkers, tau PET, FDG PET, and volumetric MRI in mild to moderate Alzheimer's disease patients

MICROGLIAL ACTIVATION AND TAU BURDEN PREDICT COGNITIVE DECLINE IN ALZHEIMER’S DISEASE

Elevated Tau PET Signal Depends on Abnormal Amyloid Levels and Correlates with Cognitive Impairment in Elderly Persons without Dementia

Prediction of Cerebral Amyloid Pathology Based on Plasma Amyloid and Tau Related Markers

IN VIVO MAPPING OF TAU DEPOSITION, PERFUSION, AND CORTICAL THINNING IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

P4‐299: TAU ACCUMULATION IN THE ENTORHINAL CORTEX AND PRECUNEUS IS ASSOCIATED WITH CORTICAL AMYLOID‐BETA BURDEN, AGE AND WORSE MEMORY PERFORMANCE IN PRECLINICAL AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE

Association Between Amyloid and Tau Accumulation in Young Adults With Autosomal Dominant Alzheimer Disease

Association of Amyloid and Tau With Cognition in Preclinical Alzheimer Disease

Tau Pathology is Associated with Synaptic Density and Longitudinal Synaptic Loss in Alzheimer’s Disease

Microglial Activation, Tau Pathology, and Neurodegeneration Biomarkers Predict Longitudinal Cognitive Decline in Alzheimer’s Disease Continuum

Evaluating the association between brain atrophy, hypometabolism, and cognitive decline in Alzheimer’s disease: a PET/MRI study

Seeing beyond the symptoms: biomarkers and brain regions linked to cognitive decline in Alzheimer's disease

Tau Pathology Mediated the Plasma Biomarkers and Cognitive Function in Patients with Mild Cognitive Impairment.

Plasma Biomarker Profiles and the Association with Cognitive Function Across the Clinical Spectrum of Alzheimer's Disease

Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer’s disease

P-tau and Neurodegeneration Mediate the Effect of Β-Amyloid on Cognition in Non-Demented Elders